TDP1; HSD17B1; POLB; | |
GAA; | |
CA7; CA4; CA12; | |
NPC1; RAB9A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.197E-10 | 7.881E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.320E-10 | 7.881E-07 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.448E-10 | 7.881E-07 | CYP19A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.811E-10 | 9.758E-07 | AOX1, CYP19A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, TBXAS1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.667E-09 | 4.538E-06 | CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.205E-09 | 5.334E-06 | CYP19A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, TBXAS1 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.920E-09 | 7.759E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.991E-08 | 2.890E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.687E-08 | 5.669E-05 | CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.917E-08 | 7.825E-05 | CYP19A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.573E-07 | 2.779E-04 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.084E-06 | 6.945E-04 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.181E-06 | 7.164E-04 | ABCG2, ABL1, CA12, CA7, EGFR, ESR1, HIF1A, MAPK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.217E-06 | 7.164E-04 | ABL1, CYP1B1, EGFR, MAPK1, TP53 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.591E-06 | 8.307E-04 | CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.173E-06 | 1.057E-03 | ABL1, BLM, CYP1B1, EGFR, ESR1, MAPK1, NPC1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.235E-06 | 1.058E-03 | CA12, CA4, CA7 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.455E-06 | 1.137E-03 | ABL1, CA7, EGFR, HIF1A, MAPK1, NPC1 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.007E-06 | 1.284E-03 | ESR1, ESR2 |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 5.565E-06 | 2.126E-03 | EGFR, ESRRB, HIF1A |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.053E-06 | 2.740E-03 | BLM, CA12, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, TP53 |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 9.012E-06 | 2.844E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 9.012E-06 | 2.844E-03 | ABL1, HIF1A |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 9.012E-06 | 2.844E-03 | GAA, MGAM |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.260E-05 | 3.661E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.584E-05 | 4.422E-03 | CYP19A1, CYP3A4, ESR1 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.800E-05 | 4.559E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 1.800E-05 | 4.559E-03 | GAA, MGAM |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.740E-05 | 4.559E-03 | CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.165E-05 | 5.228E-03 | CYP1A2, EGFR, MAPK1 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.185E-05 | 5.228E-03 | CYP19A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, EGFR, RAB9A, TBXAS1 |
BP | GO:0065007; biological regulation | GO:1900274; regulation of phospholipase C activity | 3.419E-05 | 7.675E-03 | ABL1, EGFR, ESR1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.419E-05 | 7.675E-03 | CA12, CA4, CA7 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.683E-09 | 2.457E-07 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.487E-08 | 3.275E-06 | HSD17B1; CYP1A2; CYP1B1; CYP3A4; CYP19A1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.090E-07 | 1.778E-05 | MAOA; CYP1A2; AOX1; CYP1B1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.604E-07 | 7.805E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.595E-07 | 9.472E-06 | CYP2C9; CYP1A2; CYP1B1; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.754E-06 | 7.829E-05 | CYP2C9; MGAM; MAOA; GAA; HSD17B1; TBXAS1; CYP1A2; AOX1; CYP2C19; CYP3A4; CYP19A1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.945E-06 | 8.022E-05 | MAPK1; TP53; HIF1A; EGFR |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.378E-06 | 7.991E-05 | CYP2C9; CYP1A2; AOX1; CYP3A4 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.246E-05 | 2.625E-04 | MAPK1; TP53; HIF1A; ESR1; EGFR |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.972E-06 | 9.253E-05 | CYP2C9; CYP1A2; CYP1B1; CYP3A4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.239E-06 | 9.108E-05 | SLCO1B1; SLCO1B3; CYP3A4; ABCG2 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.337E-05 | 2.625E-04 | MAPK1; ESR1; EGFR; ESR2 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.796E-05 | 3.959E-04 | CYP2C9; MAOA; MAPK1; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.657E-05 | 4.249E-04 | MAPK1; TP53; ESR1; HIF1A |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.365E-04 | 9.963E-04 | ABL1; CYP1B1; MAPK1; TP53; EGFR |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.003E-06 | 7.307E-05 | CA12; CA4; CA7 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.170E-04 | 8.990E-04 | MAPK1; TP53; EGFR |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.330E-05 | 7.154E-04 | HSD17B1; CYP1B1; CYP19A1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.578E-05 | 4.249E-04 | MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.371E-05 | 7.601E-04 | MAPK1; TP53; EGFR |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.824E-04 | 1.211E-03 | MAPK1; TP53; EGFR |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.204E-04 | 2.620E-03 | ABL1; MAPK1; HIF1A; TP53; EGFR |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.909E-04 | 1.212E-03 | MAPK1; TP53; EGFR |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.585E-04 | 1.102E-03 | CYP2C9; TBXAS1; CYP2C19 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.371E-04 | 1.442E-03 | MAPK1; TP53; EGFR |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.471E-04 | 1.443E-03 | MAPK1; ESR1; ESR2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.574E-04 | 1.445E-03 | ABL1; MAPK1; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.613E-04 | 2.405E-03 | MAPK1; TP53; EGFR |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.316E-04 | 2.334E-03 | ABL1; MAPK1; EGFR |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 6.676E-04 | 3.249E-03 | MAPK1; HIF1A; EGFR |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.068E-04 | 3.329E-03 | MAPK1; HIF1A; EGFR |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.101E-03 | 4.752E-03 | ABL1; MAPK1; TP53 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.480E-03 | 6.001E-03 | MAPK1; TP53; EGFR |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.026E-03 | 1.790E-02 | POLB; MAPK1; TP53 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.662E-03 | 2.211E-02 | ABL1; MAPK1; EGFR |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.158E-03 | 2.845E-02 | MAPK1; TP53; EGFR |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.668E-03 | 1.747E-02 | MAPK1; HIF1A |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.976E-03 | 1.790E-02 | MAPK1; TP53 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.045E-02 | 3.051E-02 | MAPK1; EGFR |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 4.079E-03 | 1.567E-02 | MGAM; GAA |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.621E-03 | 1.908E-02 | MAPK1; HIF1A |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.018E-03 | 2.277E-02 | MAPK1; EGFR |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.800E-03 | 2.981E-02 | MAPK1; EGFR |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.456E-03 | 1.897E-02 | ABL1; MAPK1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.107E-03 | 4.752E-03 | MAPK1; TP53 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 9.587E-04 | 4.374E-03 | MAPK1; EGFR |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.611E-03 | 6.358E-03 | MAOA; AOX1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.184E-03 | 4.940E-03 | MGAM; GAA |
hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 1.016E-02 | 3.027E-02 | AOX1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.472E-03 | 2.689E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |